Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches

Keymed Biosciences Reports Strong Annual Results for 2025

Keymed Biosciences, listed on the Hong Kong Stock Exchange under the ticker HKEX: 02162, has announced its annual financial results for 2025, revealing a substantial growth in revenue. The company reported a total revenue of approximately 720 million yuan, which reflects an impressive 67% increase compared to the previous year. This surge in revenue is divided between about 310 million yuan from sales of its flagship product, Kangyueda®, and around 410 million yuan stemming from collaborative revenue.

Investments in research and development remain a core priority for Keymed, with research expenditures reaching approximately 720 million yuan. As of December 31, 2025, the company holds cash reserves of roughly 1.96 billion yuan, positioning it well for future growth and innovation.

A significant milestone for Keymed was the approval by the National Medical Products Administration (NMPA) for the market authorization of Kangyueda® for various indications, including moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. Starting January 2026, all launched indications have been included in the National Reimbursement Drug List of China, significantly enhancing patient access to this medication.

During the reporting period, sales from Kangyueda® reached approximately 315 million yuan, demonstrating strong market demand. In addition, Keymed is advancing its innovative drug pipeline, particularly with CMG901 (AZD0901), the first antibody-drug conjugate targeting claudin 18.2. After securing a global development licensing agreement with AstraZeneca, several phase III trials are currently underway. The initiation of these trials has resulted in milestone payments, including a notable achievement in February 2026 when the first subject was treated in the clinical trial setting.

Furthermore, CM336, a bispecific antibody targeting BCMA x CD3, has been licensed to Ouro Medicines for global development—excluding Greater China. In March 2026, Ouro Medicines announced its acquisition by Gilead Sciences. As part of the merger agreement, an initial payment of $1.675 billion is anticipated, in addition to contingent milestone payments reaching a maximum of $500 million, totaling up to approximately $2.175 billion. Based on Keymed’s ownership stake in Ouro Medicines, the company is poised to receive an initial payment of around $250 million along with potential milestone payments of approximately $70 million.

Keymed Biosciences has established a diverse range of technological platforms, including antibody discovery, antibody-drug conjugates, bispecific T-cell engagers, oligonucleotide platforms, small molecule platforms, and antibody delivery systems that penetrate the blood-brain barrier. Leveraging synergistic innovation capabilities across its platforms, Keymed continues to develop high-quality, innovative drugs for patients worldwide.

As the company progresses into 2026, it remains committed to addressing unmet medical needs through innovative therapeutics, demonstrating a strong focus on R&D and expanding its market presence.

For more information, visit Keymed Biosciences Official Website.